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Does deterioration in mental health after
smoking cessation predict relapse to
smoking?
Gemma Taylor1*, Ann McNeill2 and Paul Aveyard3
Abstract
Background: It is possible that some people who quit smoking experience improved mental health after cessation
and therefore remain abstinent, whereas other people who quit may experience worse mental health after
cessation and therefore be more likely to relapse to smoking. Thus, in this study we aimed to examine the
association between an enduring change in mental health following the cessation period and future risk of relapse.
Methods: A secondary analysis of prospective data pooled from five placebo-controlled randomised trials for
smoking reduction conducted in Europe, USA and Australia. Change in mental health (SF-36, scored 0–100) was
measured from baseline to four months for those who were biologically-validated as point-prevalence abstainers at four
month follow-up. Thereafter we assessed whether relapse to smoking by 12 months was more likely in those whose
mental health had worsened between baseline and four months compared with those who saw no change or an
improvement.
Results: After adjustment for baseline mental health and other major covariates, there was no greater tendency to
relapse at 12 months for those whose mental health worsened after cessation compared with those who had no
change or an improvement. The odds ratio and 95 % confidence interval was 1.01 (0.97 to 1.05).
Conclusions: People whose mental health worsens after smoking cessation are at no greater risk of subsequent relapse
to smoking than those whose mental health stays the same or improves.
Keywords: Smoking cessation, Tobacco, Epidemiology, Relapse, Mental health
Background
A recent meta-analysis reported strong evidence of an
association between stopping smoking and improved
mental health [1]. This is surprising, because many
smokers perceive that smoking benefits their mental
health [2–7]. The misattribution hypothesis explains
why smoking is perceived as offering mental health ben-
efits but why stopping smoking will improve mental
health [8–10]. Chronic tobacco smoking leads to periods
of withdrawal which are characterized by restlessness,
depressed mood, irritability and anxiety [11, 12]. The hy-
pothesis recognises that these withdrawal symptoms are
also a hallmark of many mental health disorders, but are
reliably relieved by smoking despite only occurring be-
cause the person smokes in the first place. Thus the to-
bacco withdrawal cycle mimics symptoms of mental
illness, while simultaneously misleading the smoker to
believe that smoking offers psychological benefits. The
model finally suggests that mental health will improve
after cessation once the person who quit has surpassed
the withdrawal period [11, 12] and tobacco-induced
psychological withdrawal symptoms dissipate.
Although this provides a neat explanation for the find-
ings, it is at odds with other data. Adolescents with mental
health problems are more prone to take up smoking than
healthy peers, adjusting for other possible causal factors
[13, 14]. A Mendelian randomisation study suggests that
smoking may not cause worse mental health [15]. Instead,
the self-medication hypothesis proposes that smokers get
genuine benefits from smoking and thus their mental
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health would deteriorate on cessation [16]. It is likely that
these smokers may be at greater risk of returning to smok-
ing or may even decide to return as their mental health is
worse off without cigarettes than while smoking [17]. It is
possible that different groups of smokers respond differ-
ently and hence both hypotheses might be true. This ex-
planation implies that the finding that cessation improves
mental health could apply to only some smokers. Other
smokers might remain trapped in persistent smoking by
deteriorating mental health when they try to stop. In this
paper, we examine evidence for this hypothesis.
Previous studies have examined this association in the
general population. Yong et al. [18] prospectively exam-
ined the association between emotional experiences after
quitting and odds of relapsing versus remaining abstin-
ent over a four year period. After cessation, participants
rated questions such as, “Since you quit, has your ability
to calm down when you feel stressed or upset improved,
gotten worse or stayed the same?” People who perceived
their ability to calm down had worsened were at greater
risk of relapse to smoking by follow-up. These data were
weakened because participants recalled a change, and
this may have introduced bias [19–21]. It would have
been preferable to assess change in mental health by
measuring health on two occasions where people rated
their current mental health with a validated tool. Gruder
and colleagues [22] prospectively examined change in
depression scores from baseline, when participants were
smoking, to two year follow-up, when participants had
either relapsed or quit. Results indicated that change in
depression scores was not associated with relapse. Simi-
larly, Manning et al. [23] analysed data from a cessation
treatment trial to determine if change in stress from
baseline (before quitting) to six month follow-up was as-
sociated with relapse at six month follow-up. Analyses
indicated that there was no association between change
in stress scores and relapse at follow-up. However, in
these studies mental health was assessed after relapse
had occurred, thus the data cannot assess whether de-
terioration in mental health after cessation predisposes
to relapse.
Therefore, in this analysis we used data gathered pro-
spectively in studies that recorded mental health at entry
to a smoking reduction trial, and then for people who
quit at four months after trial entry in the expectation
that, for many, the acute withdrawal period would have
passed. We then assessed whether the change in mental
health between trial entry and four months was associ-
ated with subsequent relapse to smoking at 12 months.
Methods
This study followed STROBE reporting guidelines for
observational studies [24].
Study design
This was a secondary analysis of prospective individual
level patient data from five merged placebo-controlled
randomised trials (RCTs) of nicotine replacement ther-
apy (NRT) for smoking reduction which were conducted
in Europe, USA and Australia. These data were provided
by McNeil pharmaceutical company, who played no role
in analysis, data interpretation or the writing of this
paper. All these trials were carried out to a consistent
protocol which included adults who smoked for at least
three years and were motivated to reduce their smoking,
but not to quit during the first month of the trial. Smok-
ing cessation was recommended as the ultimate goal
throughout the trials, but was not mandatory. Partici-
pants were excluded if they were deemed medically unfit
by a practitioner, pregnant or breastfeeding or partaking
in another smoking intervention (see reports of trials for
further details [25–28]. These trials measured the vari-
ables of interest to this study consistently at four and
12 month follow-ups, therefore to maximise the sample
size we chose these time points.
Ethics statement
Each trial received ethical approval from the appropriate
bodies within the country it was conducted, and trials
were conducted in accordance with the ethical principles
outlined in the Declaration of Helsinki. See reports of
trials for further details [25–28].
Consent statement
All participants provided informed consent to participate
in the trials. See reports of trials for further details [25–28].
Participants and study size
Seven-hundred-and-forty-one participants enrolled in
the trials provided data at baseline, four and 12 month
follow-up. One hundred and seven participants were
biologically-validated as quit at four month follow-up.
Of these, 80 participants provided sufficient data at
12 month follow-up to determine their relapse to smok-
ing status with biological validation and this abstinent
group formed the cohort for this study.
Variables
Exposure
The exposure was defined as change in mental health
from when the person was a smoker at trial entry (base-
line), to after they had been abstinent for at least seven
days at the four month follow up. All cessation out-
comes were biologically verified by exhaled carbon mon-
oxide (CO < 10 ppm). Mental health was measured using
the “emotional wellbeing” subscale from the RAND-36/
SF-36 item health survey 1.0. Scores range from 0 to
100, an increase on the scale indicates improved mental
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health and scores of ≤38 indicates presence of a mental
health problem. In the general population the subscale
mean and standard deviation are 70 [22, 29, 30]. The
scale correlates highly with other mental health mea-
sures, and is available in multiple languages and valid in
many countries [31].
Outcome
The outcome was bio-validated smoking at 12 months or
bio-validated point-prevalence abstinence at 12 months.
Those whose carbon monoxide level did not confirm either
smoking or quitting at four or 12 month follow-ups were
not included in the analysis. Figure 1 explains the measure-
ment of exposure and outcome.
Confounding variables
The following variables were potential confounders of
the association between change in mental health and
quit attempt success: Nicotine dependence, as measured
using the Fagerström Test of Nicotine Dependence
(FTND) [32]. Higher nicotine dependence has been
found to be associated with worse mental health and
quit attempt success [3, 34]. NRT treatment status (pla-
cebo or active) was added as active treatment has been
found associated with quit success [35]. Sex and age have
both been found associated with smoking status and men-
tal health [36]. Baseline mental health scores (SF-36) may
predict quit success and will also be the strongest predic-
tors of inter-individual change [37–39].
Statistical methods
To maximise the power of the analyses, we examined
the association between change in mental health be-
tween baseline and four months and risk of relapse as a
linear term, rather than dichotomising the data [40]. Lo-
gistic regression modelling was used to assess the associ-
ation between change in mental health and relapse, a
dummy variable was created for smoking status,
repeated-point prevalence abstinence was indicated by
‘0’, and relapse indicated by ‘1’. We inversely scaled
change in mental health by subtracting four month
follow-up scores from baseline scores. The odds ratios
therefore represented the odds of relapsing for a
deterioration in mental health. The regression model
was repeated with and without adjustment for FTND
score, NRT treatment status, baseline mental health
(SF-36), trial, sex and age.
Sensitivity analysis
We chose the four-month follow up point so as to maxi-
mise opportunity to avoid the acute withdrawal period
after cessation, but, given the quit date varied for
smokers who stopped, the analysis could have included
only recently abstinent smokers whose mental health
could have deteriorated because they were suffering
withdrawal. We were interested in those smokers who
had been through the acute withdrawal period and sub-
sequently suffered a more enduring deterioration in
mental health. We addressed this in a sensitivity analysis
by repeating the analysis excluding recently abstinent
smokers and included only those abstinent at both
10 week and 4 month follow-up (Fig. 2).
Risk of bias
An adapted version of the Newcastle-Ottawa Scale
was used to assess risk of bias in observational studies
[1, 41]. The measure rates studies on a scale of 1 to 5: 1 in-
dicates a high risk of bias and 5 indicates a low risk of bias.
Results
Participants
One-hundred-and-seven participants were biologically-
validated as quit at four months. Of these, 80 reported
smoking status at 12 months. The 27 participants who
did not provide smoking data at 12 months and who
were excluded from the analysis were on average psy-
chologically healthy, according to the SF-36 [29], with a
mean (M) and standard deviation (SD) of 71.7 (21.2). Of
the 80 participants reporting outcome data at four and
12 months, two people who quit were excluded as they
did not have data on mental health. After excluding for
missing data, the analysis included 17 people who quit
(21 %) classified as relapsed to smoking at 12 month
follow-up, and 61 as quit at 12 month follow-up.
Baseline 4 Months 12 Months
Bio-verified 
quit 
Smoker Bio-verified 
Relapse vs. quit
Mental health
Fig. 1 Timeframe for measurement of exposure and outcome variables
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Characteristics of people who quit and those who
relapsed to smoking
Baseline characteristics of people who quit and those
who relapsed are presented in Table 1. The groups were
not significantly different in age, sex, nicotine depend-
ency (FTND), baseline mental health (SF-36) or receipt
of active NRT (Table 1).
Logistic regression analyses
On average, both those who reported smoking relapse
and those who remained abstinent reported small and
similar improvements in mental health between baseline
(smoking) and four month follow-up (abstinent). The
mean (SD) improvements were 2.2 (14.8), and 3.1 (17.6)
respectively. Mental health deteriorated between base-
line and four months in 50 % (n = 30) of people who
would remain abstinent to 12 months and deteriorated
in 55 % (n = 6) of people who would relapse by
12 months.
The unadjusted model indicated that change in mental
health from baseline to four months was not associated
with odds of relapsing, compared with staying quit, odds
ratio and 95 % confidence intervals (OR; 95 % CI) was
1.00 (0.96 to 1.03), P = 0.84. After adjustment for base-
line mental health, FTND scores, NRT status, trial, age
and sex, the association remained non-significant, 1.01
(0.97 to 1.05), P = 0.65 (Table 2).
Sensitivity analysis
Excluding people who quit at four months (N = 28) did
not change the results. Of the five people who relapsed,
and the 45 people who were quit (repeated point-
prevalence), there remained no association between
change in mental health from baseline to four month
follow, and relapse at 12 month follow-up, OR (95 % CI)
was 1.01 (0.95 to 1.07), P = 0.73. Adjustment for covari-
ates did not change the association, OR 1.01 (0.94 to
1.08), P = 0.82.
Risk of bias
The study scored 4 out of 5, indicating a low risk of bias
[41], one point was lost for high attrition (Additional file 1).
Discussion
In this study we aimed to examine whether an enduring
deterioration in mental health following smoking cessa-
tion was associated with future relapse to smoking. On
average, people who quit and those who relapsed to
smoking showed small improvements in mental health
after they stopped smoking. However, some showed a
deterioration but there was no evidence that worsening
mental health between baseline and four months was as-
sociated with relapse to smoking by 12 months.
Limitations, strengths and potential sources of bias
Although the cohort was small, the confidence intervals
were narrow enough to exclude the possibility of even a
moderate sized association. The use of a validated tool
to measure mental health assessed on two occasions to
assess change in mental health added validity [29]. In
this dataset we were able to assess, for a subsample,
mental health after the acute withdrawal period follow-
ing cessation, thereby measuring a more enduring
change in mental health. It is possible however, that
some people whose mental health deteriorated over and
beyond the acute withdrawal stage had already relapsed
Baseline 4 Months 12 Months
Bio-verified 
quit 
Smoker Bio-verified 
Relapse vs. quit
Mental health
10 Weeks
Bio-verified 
quit 
Fig. 2 Timeframe for measurement of exposure and outcome variables in the sensitivity analysis
Table 1 Baseline (trial entry) characteristics of people who were quit or relapsed at 12 month follow-ups
Characteristic Quit at 12 months (N = 61) Relapsed at 12 months (N = 17) P-value
Age, M (SD) 46.9 (9.6) 45.3 (11.9) 0.58
Sex, % male (N) 49 % (30) 71 % (12) 0.12
FTND, M (SD) 5.5 (2.4) 5.6 (1.5) 0.80
SF-36 Mental health, M (SD) 74.5 (14.7) 69.6 (18.0) 0.24
Treatment status, % received active (N) 72 % (44) 71 % (12) 0.90
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by four months and hence were not captured in our co-
hort. In addition, the trials analysed in this study ex-
cluded participants if they were under the care of a
psychiatrist, thus these findings may not be generalizable
to people with a longstanding or severe mental illness.
Pre-cessation scores were measured at baseline while
everyone was a smoker and had no immediate plans to
quit, only to reduce. It is possible that smokers who
were motivated to reduce had better mental health than
those who were not motivated, and this may limit gener-
alisability of the results; however, there are no available
studies to support this possibility. Post-cessation mental
health scores were obtained at four month follow-up,
when smokers had stopped and were proven to have
stopped. Use of point-prevalence criteria to ascertain ab-
stinence may have included some people who were not
continuously abstinent for at least 6 weeks at the
4 month follow-up [42, 43]; thus some participants may
have been experiencing withdrawal, in-turn influencing
mental health scores [11, 12]. However a sensitivity ana-
lysis confined to people who were continuously abstin-
ent at both 10 week and four month follow-up gave very
similar results, therefore it is unlikely that mental health
scores were affected. We used biologically-validated
point-prevalence abstinence to define relapse between
four and 12 months. It is possible that those who were
biologically-validated as quit at both time-points may
have relapsed but resumed abstinence and this possible
outcome misclassification may underestimate the true
strength of the association. However, it would be un-
common to find a smoker who was quit at both time
points but had smoked in between [42, 43] and therefore
we believe the degree of underestimation to be minimal.
Interpretation
The finding of this study concurs with other studies that
assessed mental health with psychometrically appropri-
ate measures [22, 23]. Gruder et al. found that change in
symptoms of depression and stress from baseline to
follow-up were not associated with relapse to smoking
[22], and Manning and colleagues [23] replicated these
findings for symptoms of stress. However, these studies
assessed mental health after relapse, meaning that it is
possible that relapsing and reinstatement of the thera-
peutic benefits of smoking masked the association be-
tween worsening mental health and relapse. We did not
have the same difficulty in this study. In addition, these
other studies had odds ratios for the association close to
one which were not changed much by adjustment, as in
our study, but our study provides greater precision. The
only data contradicting this study were reported by Yong
et al. [18], which showed that smokers who reported
that their ability to cope with negative affect had deterio-
rated after abstinence were more likely to relapse in the
future. However, their study did not assess mental health
when smoking and when abstinent. Reports of mental
health change were based upon participants’ memory
and this may have introduced bias. Reports of emotional
symptoms from memory are well known to become less
accurate and more biased over time; [19, 44–48] making
the validity of such reports suspect and clouding the re-
ported association. Given we found no evidence of this
in a more robust design, we suggest the evidence does
not favour this hypothesis.
Conclusions
We found no evidence that there is an increased risk of
relapse to smoking for those whose mental health
worsens. It may be that the apparent improvement in
mental health on cessation is likely to apply to all
smokers. These findings have implications for cessation
treatment in allaying concerns that smokers will not be
able to emotionally cope without cigarettes and thus
leading them to return to smoking. The findings of Yong
and colleagues could suggest that smokers who believe
that smoking is stress relieving are at increased risk of
relapse [18]. It is now possible to address this belief dir-
ectly. There is clear evidence from a systematic review
and meta-analysis that mental health improves in most
people who stop smoking and that it does not worsen in
general [1], and, even for those that experience a wors-
ening, this may not cause relapse. In addition to this re-
assurance, providing alternative and well-practised
methods to manage stress may prevent relapse caused
by this belief.
Additional file
Additional file 1: Supplementary material. (DOCX 18 kb)
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Table 2 SF-36 Mental health scores at four and 12 month follow-ups for people who quit or relapsed by 12 month
Quit at 12 months (N = 61) Relapsed at 12 months (N = 17)
SF-36 Mental health at 4 month follow-up, M (SD)a 76.7 (13.7) 72.7 (19.5)
SF-36 Mental health at 12 month follow-up, M (SD)a 77.1 (15.8) 70.4 (16.3)
aNo significant differences between groups SF-36 scores at 4 or 12 month follow-ups. Mean scores indicated the groups were psychologically healthy at both
follow-ups. 28
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